# Richel Liu

> Richel Liu is a Series A investor at Rimonci Capital backing Medical Device and Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Rimonci Capital](https://shizune.co/investors/profile/rimonci-capital)
- Location: Beijing, China
- Total investments: 6
- Last investment: Feb 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/richel-liu-166b6313a/?originalSubdomain=cn

Richel Liu is a Founder and CEO of Rimonci Capital. She attended Xi'an University of Technology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 4 | 67% |
| Health Care | 3 | 50% |
| Laser | 1 | 17% |
| Eyewear | 1 | 17% |
| Medical | 1 | 17% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Seed | 1 | 17% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 3 | 50% |
| France | 1 | 17% |
| United States | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TECLens | TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore. | $9.3M | Series A | Feb 11, 2025 |  |
| Laclarée | Laclarée develops a pair of adaptive eyeglasses for presbyopia. Its patented technology allows the eyeglasses to adapt in real-time to the scene viewed by the wearer. This major innovation will help milllions of people 45+ years, who are not satisfied with current solutions (progressive lenses, multiple pairs, etc...). | $3.6M | Seed | Jan 28, 2025 |  |
| EyeYon | EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $25M | Series C | Mar 15, 2021 |  |
| BELKIN Vision | BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $12.3M | Series B | Jul 21, 2020 |  |
| NovaSight | NovaSight brings pediatric vision care into the digital age. Our integrated eye-tracking AI based solutions for accurate vision assessment and efficient treatment are specifically designed for the unique needs and attention span of children.NovaSight’s management and scientific advisory board is comprised of experienced executives, researchersand key opinion leaders in the field of pediatric vision care. | $8M | Series A | Jul 13, 2020 |  |
| BELKIN Vision | BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $6.6M | Series A | Jun 05, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [CR-CP Life Science Fund](https://shizune.co/investors/profile/cr-cp-life-science-fund) — VC Fund, 2 deals together
- [BPC Investments](https://shizune.co/investors/profile/bpc-investments) — VC Fund, 1 deal together
- [Diamond Biofund Inc.](https://shizune.co/investors/profile/diamond-biofund) — VC Fund, 1 deal together
- [European Union](https://shizune.co/investors/profile/european-union) — VC Fund, 1 deal together
- [Global health sciences venture fund](https://shizune.co/investors/profile/global-health-sciences-venture-fund) — VC Fund, 1 deal together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 1 deal together

## About Rimonci Capital

VC Fund · Beijing, China

A dedicated to China-Israel cross border investment.

2 contacts available at Rimonci Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Richel Liu | Founder and CEO | https://shizune.co/investors/profile/richel-liu |
| Eddie Wang | COO and Co-Founder | https://shizune.co/investors/profile/eddie-wang-0a5e |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Richel Liu invest in?

Richel Liu invests primarily in Medical Device, Health Care and Laser startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Richel Liu last invest?

The most recent investment recorded for Richel Liu closed in Feb 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co